Review





Similar Products

95
MedChemExpress hdac2 inhibition assay
Hdac2 Inhibition Assay, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac2/HDAC2+Antibody/pm42965736-55-24-34
Average 95 stars, based on 1 article reviews
hdac2 inhibition assay - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

91
Sino Biological hdac2
Hdac2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac2/HDAC2%2C+Active/pm42911727-341-10-11
Average 91 stars, based on 1 article reviews
hdac2 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

94
BPS Bioscience hdac2
Hdac2, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac2/HDAC2%2C+His-tag+Recombinant/pm42994190-549-4-28
Average 94 stars, based on 1 article reviews
hdac2 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
Proteintech hdac2
Hdac2, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac2/HDAC2+Antibody/pm42929872-128-94-96
Average 95 stars, based on 1 article reviews
hdac2 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc antibodies alpha tubulin dm1a mouse
Antibodies Alpha Tubulin Dm1a Mouse, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac2/HDAC2+Antibody/pm42875546-701-28-27
Average 96 stars, based on 1 article reviews
antibodies alpha tubulin dm1a mouse - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
ABclonal Biotechnology anti hdac2
Anti Hdac2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac2/HDAC2+Rabbit+mAb/pm42826558-45-203-205
Average 94 stars, based on 1 article reviews
anti hdac2 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
BPS Bioscience fluorogenic hdac2 assay kit
Fluorogenic Hdac2 Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac2/HDAC2+Fluorogenic+Assay+Kit/pm42805174-972-22-26
Average 94 stars, based on 1 article reviews
fluorogenic hdac2 assay kit - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
Proteintech antibodies against hdac2
A simple yet powerful label-free strategy was developed to directly convert drug molecules into fluorescent probes, enabling cellular imaging and orchestrating a lysosome-mitochondria-nucleus interplay that elicits nuclear ROS (nuROS) generation. This, in turn, activates an uncharacterized <t>nuROS-HDAC2-EMT</t> axis, thereby abrogating metastasis.
Antibodies Against Hdac2, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac2/HDAC2+Antibody/pmc13634123-177-18-22
Average 95 stars, based on 1 article reviews
antibodies against hdac2 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc hdac2 3f3 mouse
A simple yet powerful label-free strategy was developed to directly convert drug molecules into fluorescent probes, enabling cellular imaging and orchestrating a lysosome-mitochondria-nucleus interplay that elicits nuclear ROS (nuROS) generation. This, in turn, activates an uncharacterized <t>nuROS-HDAC2-EMT</t> axis, thereby abrogating metastasis.
Hdac2 3f3 Mouse, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac2/HDAC2+Mouse+mAb/10__1038_slash_s42003___026___10753___4-295-104-107
Average 95 stars, based on 1 article reviews
hdac2 3f3 mouse - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


A simple yet powerful label-free strategy was developed to directly convert drug molecules into fluorescent probes, enabling cellular imaging and orchestrating a lysosome-mitochondria-nucleus interplay that elicits nuclear ROS (nuROS) generation. This, in turn, activates an uncharacterized nuROS-HDAC2-EMT axis, thereby abrogating metastasis.

Journal: Materials Today Bio

Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

doi: 10.1016/j.mtbio.2026.103681

Figure Lengend Snippet: A simple yet powerful label-free strategy was developed to directly convert drug molecules into fluorescent probes, enabling cellular imaging and orchestrating a lysosome-mitochondria-nucleus interplay that elicits nuclear ROS (nuROS) generation. This, in turn, activates an uncharacterized nuROS-HDAC2-EMT axis, thereby abrogating metastasis.

Article Snippet: In the immunohistochemical analysis, the sections were incubated with 3% BSA for 30 min before being exposed to antibodies against HDAC2 (1:2000; Proteintech, 12922-3-AP), E-cadherin (1:300; Immunoway, YT1454) or Vimentin (1:300; Immunoway, YT5796).

Techniques: Imaging

The supratargeting mechanism through proteomics analysis. (a) Volcano plots of differentially expressed proteins (DEPs) in 4T1 cells treated with Control or diNP@PDs (25 μM). Proteins are represented by dots, with upregulated proteins highlighted in red and downregulated proteins in blue. (b) Proteomics analysis showing DEPs in distinct subcellular compartments of 4T1 cells treated with Control or diNP@PDs. The subcellular structure annotations for DEPs were classified based on Gene Ontology (GO) analysis. (c) PRM-based proteomic profiling elucidates multi-organelle targeting mechanism of diNP@PDs. Through high-resolution parallel reaction monitoring (PRM) targeted proteomics. (d-e) GO enrichment analysis of up-regulated (d) and down-regulated (e) genes in diNP@PDs compared to control groups. (f-g) GSEA enrichment analysis (f) and KEGG pathway (g) of lysosome-related genes. (h,i) Circos plots of upregulated ( h ) or downregulated ( i ) DEPs and their associated enriched pathways. (j) Venn diagram of the most differential survival genes from GEPIA2, DEPs and proteins relative to L-M-N. (k) Relative protein levels of 27 proteins located in lysosomes, mitochondria, and nuclei identified via Venn diagram. (l ) Survival analysis plots of nuclear HDAC2 in breast invasive carcinoma (BRCA) patients using the GEPIA database ( http://gepia.cancer-pku.cn/ ). (m ) A Gene Set Enrichment Analysis (GSEA) for pathway enrichment of Reactive Oxygen Species based on identified DEPs, represented by normalized enrichment score (NES) and nominal p value.

Journal: Materials Today Bio

Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

doi: 10.1016/j.mtbio.2026.103681

Figure Lengend Snippet: The supratargeting mechanism through proteomics analysis. (a) Volcano plots of differentially expressed proteins (DEPs) in 4T1 cells treated with Control or diNP@PDs (25 μM). Proteins are represented by dots, with upregulated proteins highlighted in red and downregulated proteins in blue. (b) Proteomics analysis showing DEPs in distinct subcellular compartments of 4T1 cells treated with Control or diNP@PDs. The subcellular structure annotations for DEPs were classified based on Gene Ontology (GO) analysis. (c) PRM-based proteomic profiling elucidates multi-organelle targeting mechanism of diNP@PDs. Through high-resolution parallel reaction monitoring (PRM) targeted proteomics. (d-e) GO enrichment analysis of up-regulated (d) and down-regulated (e) genes in diNP@PDs compared to control groups. (f-g) GSEA enrichment analysis (f) and KEGG pathway (g) of lysosome-related genes. (h,i) Circos plots of upregulated ( h ) or downregulated ( i ) DEPs and their associated enriched pathways. (j) Venn diagram of the most differential survival genes from GEPIA2, DEPs and proteins relative to L-M-N. (k) Relative protein levels of 27 proteins located in lysosomes, mitochondria, and nuclei identified via Venn diagram. (l ) Survival analysis plots of nuclear HDAC2 in breast invasive carcinoma (BRCA) patients using the GEPIA database ( http://gepia.cancer-pku.cn/ ). (m ) A Gene Set Enrichment Analysis (GSEA) for pathway enrichment of Reactive Oxygen Species based on identified DEPs, represented by normalized enrichment score (NES) and nominal p value.

Article Snippet: In the immunohistochemical analysis, the sections were incubated with 3% BSA for 30 min before being exposed to antibodies against HDAC2 (1:2000; Proteintech, 12922-3-AP), E-cadherin (1:300; Immunoway, YT1454) or Vimentin (1:300; Immunoway, YT5796).

Techniques: Proteomic Assay, Analysis, Control, Profiling, Targeted Proteomics, Gene Set Enrichment Analysis, Significance Assay

Inhibiting tumor metastasis via HDAC2 sensing nuclear ROS. (a) Representative confocal images of intracellular ROS generation after the indicated treatment. (b) Dose-response relationship of ROS production in 4T1 cells after 24 h treatment with diNP@PDs (5-50 μM). (c) Time-course analysis of ROS generation in 4T1 cells treated with 20 μM diNP@PDs. (d-f) Nuclear ROS (nuROS) in 4T1 cells post-treatment. Quantitative analysis of nuROS levels by flow cytometry (d-e) . Purple bars: nuROS levels after various treatment, measured via DCFH-DA staining; Blue bars: drug fluorescence in the FITC channel after cellular uptake (f) . Nuclear fractions were isolated using a Nuclear Extraction Kit (Solarbio®), following manufacturer's protocol. (g-h) HDAC2 immunofluorescence in 4T1 cells treated with Cur (6.25 μM), Sora (25 μM) and diNP@PDs (25 μM) for 12 h. (i ) Immunoblotting analysis of HDAC2 expression after the indicated treatment. (j ) Flow cytometry analysis of cellular ROS levels after indicated treatments with the ROS inhibitor NAC or diNP@PDs. (k,l ) Representative confocal images ( k ) and mean intensity values ( l ) of cellular immunofluorescence of HDAC2 after indicated treatments with the ROS inhibitor NAC or diNP@PDs. Scale bar, 10 μm. (m-n ) Representative images ( m ) and quantitative analysis ( n ) of wound healing assay to measure the migration ability of the HDAC2 inhibitor SAHA and diNP@PDs. (o ) Schematic illustration of the mechanism underlying tumor metastasis inhibition via the nuROS-HDAC2-EMT pathway. Data are shown as mean ± s.d. Statistical significance of p values in b,c,e,f,h,j,l was calculated via one-way ANOVA with a Tukey post-hoc test, and this in n was calculated by a two-tailed Student's t-test.

Journal: Materials Today Bio

Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

doi: 10.1016/j.mtbio.2026.103681

Figure Lengend Snippet: Inhibiting tumor metastasis via HDAC2 sensing nuclear ROS. (a) Representative confocal images of intracellular ROS generation after the indicated treatment. (b) Dose-response relationship of ROS production in 4T1 cells after 24 h treatment with diNP@PDs (5-50 μM). (c) Time-course analysis of ROS generation in 4T1 cells treated with 20 μM diNP@PDs. (d-f) Nuclear ROS (nuROS) in 4T1 cells post-treatment. Quantitative analysis of nuROS levels by flow cytometry (d-e) . Purple bars: nuROS levels after various treatment, measured via DCFH-DA staining; Blue bars: drug fluorescence in the FITC channel after cellular uptake (f) . Nuclear fractions were isolated using a Nuclear Extraction Kit (Solarbio®), following manufacturer's protocol. (g-h) HDAC2 immunofluorescence in 4T1 cells treated with Cur (6.25 μM), Sora (25 μM) and diNP@PDs (25 μM) for 12 h. (i ) Immunoblotting analysis of HDAC2 expression after the indicated treatment. (j ) Flow cytometry analysis of cellular ROS levels after indicated treatments with the ROS inhibitor NAC or diNP@PDs. (k,l ) Representative confocal images ( k ) and mean intensity values ( l ) of cellular immunofluorescence of HDAC2 after indicated treatments with the ROS inhibitor NAC or diNP@PDs. Scale bar, 10 μm. (m-n ) Representative images ( m ) and quantitative analysis ( n ) of wound healing assay to measure the migration ability of the HDAC2 inhibitor SAHA and diNP@PDs. (o ) Schematic illustration of the mechanism underlying tumor metastasis inhibition via the nuROS-HDAC2-EMT pathway. Data are shown as mean ± s.d. Statistical significance of p values in b,c,e,f,h,j,l was calculated via one-way ANOVA with a Tukey post-hoc test, and this in n was calculated by a two-tailed Student's t-test.

Article Snippet: In the immunohistochemical analysis, the sections were incubated with 3% BSA for 30 min before being exposed to antibodies against HDAC2 (1:2000; Proteintech, 12922-3-AP), E-cadherin (1:300; Immunoway, YT1454) or Vimentin (1:300; Immunoway, YT5796).

Techniques: Confocal, Analysis, Flow Cytometry, Staining, Fluorescence, Isolation, Extraction, Immunofluorescence, Western Blot, Expressing, Wound Healing Assay, Migration, Inhibition, Two Tailed Test

diNP@PDs-induced L-M-N contacts in vivo regulate HDAC2 signaling and attenuate metastasis. (a) Schematic illustration of lung metastasis inhibition after being treated with diNP@PDs. (b) Representative bioluminescence images of tumor-bearing mice at specified time points after indicated treatments ( n = 3). (c-d) Immunohistochemical staining ( c ) and quantitative analysis ( d ) of EMT markers after indicated treatment. Scale bar, 25 μm. (e-f) HDAC2 expression in metastatic lungs after indicated treatment. Scale bar, 100 μm. (g) Representative confocal images of L-M-N contacts in metastasis-bearing lungs stained for LAMP1 (lysosome), TOMM20 (mitochondrion), and Lamin B1 (nucleus). Scale bar, 10 μm. Data are shown as mean ± s.d.

Journal: Materials Today Bio

Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

doi: 10.1016/j.mtbio.2026.103681

Figure Lengend Snippet: diNP@PDs-induced L-M-N contacts in vivo regulate HDAC2 signaling and attenuate metastasis. (a) Schematic illustration of lung metastasis inhibition after being treated with diNP@PDs. (b) Representative bioluminescence images of tumor-bearing mice at specified time points after indicated treatments ( n = 3). (c-d) Immunohistochemical staining ( c ) and quantitative analysis ( d ) of EMT markers after indicated treatment. Scale bar, 25 μm. (e-f) HDAC2 expression in metastatic lungs after indicated treatment. Scale bar, 100 μm. (g) Representative confocal images of L-M-N contacts in metastasis-bearing lungs stained for LAMP1 (lysosome), TOMM20 (mitochondrion), and Lamin B1 (nucleus). Scale bar, 10 μm. Data are shown as mean ± s.d.

Article Snippet: In the immunohistochemical analysis, the sections were incubated with 3% BSA for 30 min before being exposed to antibodies against HDAC2 (1:2000; Proteintech, 12922-3-AP), E-cadherin (1:300; Immunoway, YT1454) or Vimentin (1:300; Immunoway, YT5796).

Techniques: In Vivo, Inhibition, Immunohistochemical staining, Staining, Analysis, Expressing, Confocal

Journal: Materials Today Bio

Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

doi: 10.1016/j.mtbio.2026.103681

Figure Lengend Snippet:

Article Snippet: In the immunohistochemical analysis, the sections were incubated with 3% BSA for 30 min before being exposed to antibodies against HDAC2 (1:2000; Proteintech, 12922-3-AP), E-cadherin (1:300; Immunoway, YT1454) or Vimentin (1:300; Immunoway, YT5796).

Techniques: